In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

A case of hemorrhagic tamponade due to right atrium angiosarcoma

Session Poster Session 2 - Clinical Cases

Speaker Thai Hao Phan

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure - Clinical
  • Session type : Poster Session
  • FP Number : P1343

Authors : H Phan (Ho Chi Minh,VN)

15 views

Authors:
H Phan1 , 1Pham Ngoc Thach University of Medicine, Cardiology - Ho Chi Minh - Vietnam ,

Citation:

Background: Primary cardiac angiosarcoma is rare. It is typically located in the right atrium and manifests as right-sided heart failure or cardiac tamponade. Most patients are symptomatic at presentation and when disease is discovered, it is often late in its course, resulting in a poor prognosis. We describe a case of hemorrhagic tamponade due to right atrium angiosarcoma. 


Case presentation: A healthy 53-year-old man presented to lung diseases hosptital after one month of hemoptysis. He was started on antibiotics for suspected pneumonia. Over the next few weeks, the hemoptysis worsened and a chest computer tomography was performed.The result was a tumor in right atrium, then he was referred to our institution for further evaluation. Cardiac MS-CT showed a heterogeneous tumor in right atrium 6.5 x 8.0 x 8.0 cm in size suspected angiosarcoma, moderated pericardial effusion (Fig.) PET-CT showed hypermetabolic tumor in right atrium, paratracheal lymph nodes and intrapulmonary nodes. Over one week he suddenly developed dyspneic, hypotensive, and tachycardia. Examination revealed distended jugular veins, distant heart sounds, and diminished lung sounds at the bases. A transthoracic echocardiogram demonstrated a large circumferential pericardial effusion with evidence of cardiac tamponade. He was transfered to emergency surgery. A large amount of blood was found in the pericardial space. Direct invasion of the tumor to the pericardium detected. The tumor was located on the wall of the right atrium and extended over the epicardium. Bleeding from the tumor had ceased after sewing and blood drainage. A piece of tumor was resected and the pathological examination revealed primary cardiac angiosarcoma. 

Discussion: Primary cardiac angiosarcomas are rare. Most patients present with symptoms related to heart failure and tamponade.The patient described here had numerous extensive pulmonary metastases, hemoptysis and tamponade. The majority of the primary tumor site is located in the right atrium, and the most common site for metastasis is the lung or the pericardium. Computed tomography scanning confirms the diagnosis of a cardiac mass.

Conclusion: Primary cardiac angiosarcomas-such as our patient's tumor-are highly aggressive and locally invasive. The tumor usually arises from the right atrium, with nonspecific symptoms and signs. Very rarely, the tumor presents with rupture, which leads to hemopericardium, cardiac tamponade, and a poor prognosis. In our patient, the surgery also controlled the bleeding and prevented death from cardiac tamponade; further, it provided a tissue specimen for diagnosis.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are